TapewireFind a company

person · Reporting owner

Ciaramella Giuseppe

Disclosed activity across 1 company

Tapewire entity
36344
SEC CIK
0001786322

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Beam Therapeutics Inc.BEAM · Entity 4227PresidentSeptember 24, 2026September 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Beam Therapeutics Inc.

Report date September 24, 2026 · Filed September 25, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect130,504 Reported balance After 2026-09-24 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-24 · Gift · Disposed 123,407 · Balance 130,504

F1: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust.

Common StockSEC Table I · non-derivativeIndirectBy spousal trust123,407 Reported balance Holding disclosure · report date 2026-09-24 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 123,407

F1: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust.

Filing footnotes · ownership attribution and instrument terms

F1: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 24, 2026 Filed Sep 25, 2026 20:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GiftCommon Stock 123,407 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-402814 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,504

F1 · balance_after: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust.

Read SEC document
June 17, 2026 Filed Jun 22, 2026 20:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 29,000 $0.00 Strike: $1.03 $0.00
Disclosure

SEC source: 0001193125-26-277509 · ownership.xml · derivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,946

Underlying: Common Stock · 29,000 shares

Expires 2028-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to these stock options vested 25% on the first anniversary of the vesting commencement dates, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

Read SEC document
June 17, 2026 Filed Jun 22, 2026 20:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 6,505 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001193125-26-277509 · ownership.xml · derivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,505 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to these stock options vested 25% on the first anniversary of the vesting commencement dates, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

Read SEC document
June 17, 2026 Filed Jun 22, 2026 20:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 29,000 $1.03 $29,870.00
Disclosure

SEC source: 0001193125-26-277509 · ownership.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 17, 2026 Filed Jun 22, 2026 20:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 6,505 $0.67 $4,358.35
Disclosure

SEC source: 0001193125-26-277509 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 01, 2026 Filed Apr 6, 2026 21:34 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 11,810 $24.58 $290,289.80
Disclosure

SEC source: 0001193125-26-144054 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 218,406

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

Read SEC document
March 31, 2026 Filed Apr 2, 2026 21:15 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantCommon Stock 40,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-140508 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 230,216

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

Read SEC document
February 24, 2026 Filed Feb 26, 2026 21:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 35,000 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0001193125-26-076544 · ownership.xml · derivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 397,313

Underlying: Common Stock · 35,000 shares

Expires 2030-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

Read SEC document
February 24, 2026 Filed Feb 26, 2026 21:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 35,000 $32.00 $1,120,042.00
Disclosure

SEC source: 0001193125-26-076544 · ownership.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 190,216

F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.04, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
February 24, 2026 Filed Feb 26, 2026 21:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 35,000 $17.00 $595,000.00
Disclosure

SEC source: 0001193125-26-076544 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 225,216

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 31, 2026 Filed Feb 2, 2026 21:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantStock Option (Right to Buy) · Derivative 80,000 $0.00 Strike: $27.62 $0.00
Disclosure

SEC source: 0001193125-26-033606 · ownership.xml · derivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2036-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

Read SEC document
April 01, 2025 Filed Apr 4, 2025 01:51 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 7,434 $18.35 $136,418.36
Disclosure

SEC source: 0000950170-25-050856 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 190,216

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 23:13 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantCommon Stock 35,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-049763 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,650

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

Read SEC document
January 31, 2025 Filed Feb 3, 2025 21:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantStock Option (Right to Buy) · Derivative 70,000 $0.00 Strike: $25.92 $0.00
Disclosure

SEC source: 0000950170-25-012306 · ownership.xml · derivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2035-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

Read SEC document
December 17, 2024 Filed Dec 19, 2024 21:10 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 53,500 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0000950170-24-138447 · ownership.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,505

Underlying: Common Stock · 53,500 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

Read SEC document
December 17, 2024 Filed Dec 19, 2024 21:10 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 53,500 $0.67 $35,845.00
Disclosure

SEC source: 0000950170-24-138447 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 06, 2024 Filed Nov 8, 2024 21:10 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 51,110 $26.36 $1,347,050.05
Disclosure

SEC source: 0000950170-24-124085 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,150

F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $26.00 to $26.98, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
October 14, 2024 Filed Oct 16, 2024 20:44 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 1,457 $0.00 Strike: $7.22 $0.00
Disclosure

SEC source: 0000950170-24-115031 · ownership.xml · derivative · entry 7

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Comon Stock · 1,457 shares

Expires 2029-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F4 · derivative.exercise_date: This stock option vested as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option was fully vested.

Read SEC document
October 14, 2024 Filed Oct 16, 2024 20:44 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 12,979 $0.00 Strike: $4.22 $0.00
Disclosure

SEC source: 0000950170-24-115031 · ownership.xml · derivative · entry 6

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Comon Stock · 12,979 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

Read SEC document
October 14, 2024 Filed Oct 16, 2024 20:44 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 27,318 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0000950170-24-115031 · ownership.xml · derivative · entry 5

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Comon Stock · 27,318 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

Read SEC document
October 14, 2024 Filed Oct 16, 2024 20:44 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 51,110 $26.27 $1,342,751.70
Disclosure

SEC source: 0000950170-24-115031 · ownership.xml · nonDerivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 160,260

F2 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $26.00 to $26.56, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
October 14, 2024 Filed Oct 16, 2024 20:44 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 1,457 $7.22 $10,519.54
Disclosure

SEC source: 0000950170-24-115031 · ownership.xml · nonDerivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 211,370

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

Read SEC document
October 14, 2024 Filed Oct 16, 2024 20:44 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 12,979 $4.22 $54,771.38
Disclosure

SEC source: 0000950170-24-115031 · ownership.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 209,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

Read SEC document
October 14, 2024 Filed Oct 16, 2024 20:44 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 27,318 $0.67 $18,303.06
Disclosure

SEC source: 0000950170-24-115031 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 196,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

Read SEC document
April 03, 2024 Filed Apr 3, 2024 23:33 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantStock Option (Right to Buy) · Derivative 12,979 $0.00 Strike: $4.22 $0.00
Disclosure

SEC source: 0000950170-24-041426 · ownership.xml · derivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,979

Underlying: Common Stock · 12,979 shares

Expires 2029-02-13

F4 · derivative.exercise_date: On February 13, 2019, the Reporting Person was granted an option to purchase 12,979 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 12,979 shares.

Read SEC document
April 03, 2024 Filed Apr 3, 2024 23:33 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantStock Option (Right to Buy) · Derivative 27,318 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0000950170-24-041426 · ownership.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,318

Underlying: Common Stock · 27,318 shares

Expires 2028-05-08

F3 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase 27,318 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 27,318 shares.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:33 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 4,534 $32.12 $145,632.08
Disclosure

SEC source: 0000950170-24-041426 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 169,616

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.09 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
March 31, 2024 Filed Apr 2, 2024 20:10 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantCommon Stock 35,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-040151 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,150

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantStock Option (Right to Buy) · Derivative 70,000 $24.40 Strike: $24.40 $1,708,000.00
Disclosure

SEC source: 0000950170-24-010474 · ownership.xml · derivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

Read SEC document
October 20, 2023 Filed Oct 24, 2023 20:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 90,900 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0000950170-23-054850 · ownership.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,005

Underlying: Common Stock · 90,900 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

Read SEC document
October 20, 2023 Filed Oct 24, 2023 20:05 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 90,900 $0.67 $60,903.00
Disclosure

SEC source: 0000950170-23-054850 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 24, 2023 Filed Jul 25, 2023 22:36 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 1,206 $0.00 Strike: $7.22 $0.00
Disclosure

SEC source: 0000950170-23-034518 · ownership.xml · derivative · entry 8

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,002

Underlying: Common Stock · 1,206 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F5 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

Read SEC document
July 24, 2023 Filed Jul 25, 2023 22:36 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 1,206 $32.01 $38,604.06
Disclosure

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 5

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,250

F2 · kind: These shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.095, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 24, 2023 Filed Jul 25, 2023 22:36 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 1,206 $7.22 $8,707.32
Disclosure

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,456

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
July 21, 2023 Filed Jul 25, 2023 22:36 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 21,846 $0.00 Strike: $7.22 $0.00
Disclosure

SEC source: 0000950170-23-034518 · ownership.xml · derivative · entry 7

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,457

Underlying: Common Stock · 21,846 shares

Expires 2029-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F5 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

Read SEC document
July 21, 2023 Filed Jul 25, 2023 22:36 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 69,438 $0.00 Strike: $7.22 $0.00
Disclosure

SEC source: 0000950170-23-034518 · ownership.xml · derivative · entry 6

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,208

Underlying: Common Stock · 69,438 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F5 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

Read SEC document
July 21, 2023 Filed Jul 25, 2023 22:36 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 155,324 $32.06 $4,979,687.44
Disclosure

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,250

F2 · kind: These shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.11, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 21, 2023 Filed Jul 25, 2023 22:36 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 21,846 $7.22 $157,728.12
Disclosure

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,574

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
July 21, 2023 Filed Jul 25, 2023 22:36 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionCommon Stock 69,438 $7.22 $501,342.36
Disclosure

SEC source: 0000950170-23-034518 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 181,728

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
April 04, 2023 Filed Apr 6, 2023 00:30 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 1,754 $29.09 $51,028.95
Disclosure

SEC source: 0000899243-23-010818 · doc4.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,290

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.79 to $29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
April 03, 2023 Filed Apr 6, 2023 00:30 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 1,918 $30.31 $58,134.58
Disclosure

SEC source: 0000899243-23-010818 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,044

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

Read SEC document
March 31, 2023 Filed Mar 31, 2023 23:49 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-010138 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,962

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the BEAM through each vesting date.

Read SEC document
January 31, 2023 Filed Mar 31, 2023 23:49 UTC Beam Therapeutics Inc. BEAM · Entity 4227 GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $43.45 $0.00
Disclosure

SEC source: 0000899243-23-010138 · doc4.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-01-31

F2 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:06 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 40,297 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0000899243-23-000973 · doc4.xml · derivative · entry 10

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,905

Underlying: Common Stock · 40,297 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:06 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 4,326 $0.00 Strike: $4.22 $0.00
Disclosure

SEC source: 0000899243-23-000973 · doc4.xml · derivative · entry 9

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,326 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option award vested upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:06 UTC Beam Therapeutics Inc. BEAM · Entity 4227 Exercise / conversionStock Option (Right to Buy) · Derivative 9,106 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0000899243-23-000973 · doc4.xml · derivative · entry 8

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,106 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option award vested upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:06 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 600 $39.94 $23,964.00
Disclosure

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 7

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,962

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:06 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 1,900 $39.07 $74,233.00
Disclosure

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 6

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,562

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.82 to $39.75, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:06 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 13,704 $37.99 $520,614.96
Disclosure

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 5

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,462

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.66 to $38.48, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:06 UTC Beam Therapeutics Inc. BEAM · Entity 4227 SaleCommon Stock 37,525 $37.14 $1,393,678.50
Disclosure

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,166

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.66 to $37.65, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.